Maternal peptide or derivative peptide with CCR7 affinity effect and application thereof

By screening and optimizing the affinity peptide of CCR7 protein, the lack of polypeptides in the prior art is solved, and the blockade of CCR7-CC21/CC19 protein interaction and ERK1/2 phosphorylation inhibition are achieved, providing New anti-tumor treatment strategies were developed.

CN118955641APending Publication Date: 2024-11-15SUN YAT SEN UNIV
View PDF 0 Cites 1 Cited by

Patent Information

Application Number
CN202411309143.0
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-19
Publication Date
2024-11-15

AI Technical Summary

Technical Problem

The existing CCR7 inhibitors are mainly concentrated in small molecules, antibodies and siRNA forms. There is a lack of research on the use of polypeptides as blocking the CCR7 pathway, and the inhibitory effect on lymph node metastasis in tumor cells is limited.

Method used

Screening and optimizing a CCR7 protein affinity peptide, which has the effect of blocking the interaction of CCR7-CC21/CC19 protein, and can inhibit the phosphorylation of ERK1/2, thereby blocking lymph node metastasis, and providing a new anti-tumor treatment strategy.

Benefits of technology

This CCR7 affinity peptide not only has excellent biological activity and biosafety, but also has a simple structure, easy to modify and modify. It can effectively inhibit the phosphorylation and lymph node metastasis of ERK1/2, and provide a new and effective anti-tumor treatment strategy.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118955641A_ABST
    Figure CN118955641A_ABST
Patent Text Reader

Abstract

The invention discloses a parent peptide or a derivative peptide with a CCR7 affinity effect and application of the parent peptide or the derivative peptide. The CCR7 protein affinity peptide is shown as any one of the following items: A1) a polypeptide with an amino acid sequence of L-S-P-L-I-F-V-T-T-P-D-T; a2) a derivative polypeptide obtained by carrying out 1-3 mutations on the second-site to twelfth-site amino acid residues in the polypeptide as shown in A1); a3), a tag is connected to the N end and / or the C end of the polypeptide such as A1) or A2) to obtain the fusion polypeptide. It is found that the CCR7 protein affinity peptide has a good affinity blocking effect on CCR7-CC21 / CC19 protein interaction, can inhibit ERK1 / 2 phosphorylation and lymph node metastasis, and can provide a new effective treatment strategy and candidate molecules for improving the anti-tumor effect.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the technical field of protein polypeptides, and in particular to a parent peptide or a derivative peptide having a CCR7 affinity effect and applications thereof. Background Art

[0002] Tumor cell metastasis is the main cause of death in cancer patients. However, in patients with metastatic cancer, tumor cells usually first metastasize to the nearest lymph nodes and then gradually metastasize to blood vessels to achieve distal metastasis of tumor cells. Local lymph node metastasis is regarded as an indicator for evaluating further metastasis and death in cancer patients. Among the known chemokine receptors, CCR7, as a G protein-coupled receptor protein, can directly mediate lymph homing. In recent years, increasing evidence has shown that the high expression of CCR7 on tumor cells can mimic the chemotactic mechanism of leukocytes, which is an important factor for tumor cells to escape immune surveillance and develop lymph node metastasis.

[0003] Related studies have shown that under physiological conditions, CCR7 is mainly expressed on immune cells (such as dendritic cells, B lymphocytes, and T lymphocyte subsets), and it plays an important role in the immune system, especially in the homing of lymphocytes and the regulation of immune responses. In addition, CCR7 also plays an important role in the growth, invasion, and metastasis of tumor cells. Some tumor cells express CCR7, enabling them to respond to the chemotaxis of CCL19 and CCL21, thereby migrating into lymphatic vessels or blood vessels and promoting tumor progression and metastasis. In tumor cell lines, CCR7 has been reported to be expressed on tumor cell lines such as B16F10, 4T1, and MCF7. In vivo studies have shown that downregulating the expression of CCR7 or applying CCR7 antagonists can inhibit tumor growth, angiogenesis, and metastasis. Therefore, blocking the CCR7-CCL19 / CCL21 axis can effectively inhibit tumor growth and the occurrence of lymph node metastasis.

[0004] In preclinical studies, therapeutic strategies targeting the CCR7-CC19 / CCL21 axis include CCR7 neutralizing antibodies, interfering with CCR7 expression (siRNA), and CCR7 small molecule inhibitors. A recent study showed that the screened small molecule Cmp2105 can specifically bind to the intracellular domain of CCR7 and inhibit the activation of CCR7, but the in vivo biological activity of this small molecule and its effect on lymph node metastasis of tumor cells need further study. In addition, some researchers have found that delivering genes expressing CCR7 antagonists to tumor tissues with high CCR7 expression can effectively block CCR7-CCL21-mediated lymph node metastasis. In clinical trials, studies have also shown that CCR7 antibody therapy can effectively block the invasion and metastasis of tumor cells. In addition, some researchers have obtained the antibody CAP-100 against CCR7 through screening, which can effectively inhibit the lymph node metastasis of chronic lymphocytic leukemia and has entered the clinical trial stage (NCT04704323). These studies have demonstrated that targeting CCR7 is an effective therapeutic strategy in inhibiting lymph node metastasis of tumor cells and has important clinical application value. However, no studies have reported the use of peptides to block CCR7.

[0005] Based on this, the present invention screens polypeptides that block the CCR7 pathway and optimizes their structures, hoping to provide a new and effective therapeutic strategy for improving anti-tumor effects. Summary of the invention

[0006] The present invention aims to solve at least one of the technical problems existing in the prior art. To this end, the present invention proposes a CCR7 protein affinity peptide, which not only has a good blocking effect on the CCR7-CC21 / CC19 protein interaction, but also can inhibit the phosphorylation of ERK1 / 2 and lymph node metastasis, and can provide a new and effective treatment strategy for improving the anti-tumor effect.

[0007] The invention also provides a biological material related to the CCR7 protein affinity peptide.

[0008] The invention also provides a method for preparing the CCR7 protein affinity peptide.

[0009] The invention also provides a pharmaceutical composition.

[0010] The invention also provides a CCR7 protein detection reagent.

[0011] The present invention also proposes an application of the CCR7 protein affinity peptide or biomaterial or pharmaceutical composition in the preparation of anti-tumor drugs.

[0012] In a first aspect of the present invention, there is provided a CCR7 protein affinity peptide, wherein the CCR7 protein affinity peptide is as shown in any one of A1) to A3): A1), a polypeptide having an amino acid sequence of LSPLIFVTTPDT; A2), a derivative polypeptide obtained by subjecting the 2nd to 12th amino acid residues of the polypeptide as described in A1) to 1 to 3 mutations; A3), a fusion polypeptide obtained by connecting a tag to the N-terminus and / or C-terminus of the polypeptide as described in A1) or A2).

[0013] The CCR7 protein affinity peptide according to the embodiments of the present invention has at least the following beneficial effects: (1) The CCR7 affinity peptide screened by the present invention not only has a good blocking effect on the CCR7-CC21 / CC19 protein interaction, but also can inhibit the phosphorylation of ERK1 / 2 and lymph node metastasis without obvious toxic side effects, which can provide a new and effective therapeutic strategy for improving the anti-tumor effect.

[0014] (2) Compared with antibody drugs, the CCR7 affinity peptide of the present invention not only has excellent biological activity and biosafety, but also has the advantages of simple structure, carrying multiple functional groups, easy modification and transformation, and low synthesis cost.

[0015] In some embodiments of the present invention, the amino acid residues in the polypeptide represented by A1) are in L configuration and / or D configuration.

[0016] In some embodiments of the present invention, the polypeptide represented by A1) comprises at least 1, 2, 4, 5, 6, 7, 8, 9, 10, 11 or 12 D-configuration amino acid residues.

[0017] In some embodiments of the present invention, the polypeptide shown in A1) contains at least 2, 4, 5 or 6 D-configuration amino acid residues.

[0018] In some embodiments of the present invention, the polypeptide represented by A1) is any one of B1) to B10), B1), a polypeptide having an amino acid sequence of LSPLIFVTTPDT, wherein the amino acid residues in the polypeptide are in D configuration; B2), a polypeptide having an amino acid sequence of LSPLIFVTTPDT, wherein the 1st and 12th amino acid residues in the polypeptide are in the D configuration, and the 2nd to 11th amino acid residues are in the L configuration; B3), a polypeptide having an amino acid sequence of LSPLIFVTTPDT, wherein the 1st, 2nd, 3rd and 12th amino acid residues in the polypeptide are in the D configuration, and the 4th to 11th amino acid residues are in the L configuration; B4), a polypeptide having an amino acid sequence of LSPLIFVTTPDT, wherein the amino acid residues at positions 1, 11 and 12 of the polypeptide are in the D configuration, and the amino acid residues at positions 2 to 10 are in the L configuration; B5), a polypeptide having an amino acid sequence of LSPLIFVTTPDT, wherein the amino acid residues at positions 1, 2, 11 and 12 of the polypeptide are in the D configuration, and the amino acid residues at positions 3 to 10 are in the L configuration; B6), a polypeptide having an amino acid sequence of LSPLIFVTTPDT, wherein the amino acid residues at positions 1, 2, 3, 11 and 12 of the polypeptide are in the D configuration, and the amino acid residues at positions 4 to 10 are in the L configuration; B7), a polypeptide having an amino acid sequence of LSPLIFVTTPDT, wherein the amino acid residues at positions 1, 10, 11 and 12 of the polypeptide are in the D configuration, and the amino acid residues at positions 2 to 9 are in the L configuration; B8), a polypeptide having an amino acid sequence of LSPLIFVTTPDT, wherein the amino acid residues at positions 1, 2, 10, 11 and 12 of the polypeptide are in the D configuration, and the amino acid residues at positions 3 to 9 are in the L configuration; B9), a polypeptide having an amino acid sequence of LSPLIFVTTPDT, wherein the amino acid residues 1, 2, 3, 10, 11 and 12 of the polypeptide are in D configuration, and the amino acid residues 4 to 9 are in L configuration; B10), a polypeptide having an amino acid sequence of LSPLIFVTTPDT, wherein the amino acid residues in the polypeptide are in L configuration.

[0019] In some embodiments of the present invention, the polypeptide shown in A1) is a polypeptide having an amino acid sequence as shown in any one of SEQ ID NO.1, SEQ ID NO.14, SEQ ID NO.16 to SEQ ID NO.23.

[0020] In some embodiments of the present invention, the polypeptide represented by A1) is a polypeptide with an amino acid sequence as represented by SEQ ID NO.1, SEQ ID NO.16, SEQ ID NO.17, SEQ ID NO.21 or SEQ ID NO.22; Preferably, the polypeptide shown in A1) is a polypeptide having an amino acid sequence as shown in SEQ ID NO.1 or SEQ ID NO.16.

[0021] In some embodiments of the present invention, the derivative polypeptide is a derivative polypeptide obtained by subjecting the amino acid residues 2 to 12 of the polypeptide described in A1) to a mutation.

[0022] In some embodiments of the present invention, the derivative polypeptide is a polypeptide having an amino acid sequence as shown in SEQ ID NO.3 to SEQ ID NO.13, and the amino acid residues of the polypeptide are in D configuration.

[0023] In some embodiments of the present invention, the CCR7 protein refers to a mammalian CCR7 protein, such as a human or mouse CCR7 protein.

[0024] The second aspect of the present invention provides a biomaterial related to the CCR7 protein affinity peptide described in any one of the first aspect, wherein the biomaterial is any one of C1) to C8): C1), a nucleic acid molecule encoding the CCR7 protein affinity peptide according to any one of the first aspects; C2), an expression cassette containing the nucleic acid molecule described in C1); C3), a recombinant vector containing the nucleic acid molecule described in C1); C4), a recombinant vector containing the expression cassette described in C2); C5), a recombinant biological cell containing the nucleic acid molecule described in C1); C6), a recombinant biological cell containing the expression cassette described in C2); C7), a recombinant biological cell containing the recombinant vector described in C3); C8), a recombinant biological cell containing the recombinant vector described in C4).

[0025] In some embodiments of the present invention, the expression cassette refers to a DNA capable of expressing the CCR7 protein affinity peptide in a host cell. The DNA may include not only a promoter for initiating transcription of the CCR7 protein affinity peptide gene, but also a terminator for terminating transcription of the CCR7 protein affinity peptide gene. Furthermore, the expression cassette may also include an enhancer sequence.

[0026] In some embodiments of the present invention, the vector may be a plasmid, a cosmid, a phage or a viral vector.

[0027] In some embodiments of the present invention, the recombinant vector may be a recombinant vector obtained by inserting a DNA molecule encoding the T7 RNA polymerase mutant into the multiple cloning site of the vector.

[0028] In some embodiments of the present invention, biological cells include prokaryotic cells and eukaryotic cells. The prokaryotic cells include bacteria or algae. The eukaryotic cells include fungi, mammalian cells or insect cells. Among them, the bacteria can be Escherichia coli, such as E. coli DH5α or E. coli BL21. The recombinant organism does not contain reproductive material.

[0029] In some embodiments of the present invention, the recombinant biological cell is a recombinant biological cell obtained by introducing the nucleic acid molecule B1), the expression cassette B2) or the recombinant vector B3) into the biological cell. E. coli DH5α or E. coli The recombinant Escherichia coli was obtained by introducing the recombinant vector into BL21.

[0030] The third aspect of the present invention provides a method for preparing the CCR7 protein affinity peptide as described in any one of the first aspects, comprising preparing it by any one of solid phase synthesis, liquid phase synthesis or gene recombination expression.

[0031] In some embodiments of the present invention, the CCR7 protein affinity peptide is prepared by solid phase synthesis.

[0032] Preferably, the solid phase synthesis method is Fmoc solid phase synthesis method.

[0033] The fourth aspect of the present invention provides a pharmaceutical composition comprising the CCR7 protein affinity peptide described in any one of the first aspects, and a pharmaceutically acceptable carrier.

[0034] The term "pharmaceutically acceptable" refers to a substance that is suitable for use in humans and / or mammals without excessive adverse side effects (such as toxicity, irritation, and allergic reactions), i.e., a substance with a reasonable benefit / risk ratio. The term "pharmaceutically acceptable carrier" refers to a carrier used for the administration of a therapeutic agent, including various excipients and diluents. The choice of carrier should match the mode of administration, specifically matching according to methods well known to those of ordinary skill in the art.

[0035] In some embodiments of the present invention, the pharmaceutically acceptable carrier comprises at least one of water, saline, buffer, glycerol, ethanol, liposomes, lipids, proteins, protein-antibody conjugates, peptides, cellulose, and nanogels.

[0036] In some embodiments of the present invention, while retaining the activity of the CCR7 protein affinity peptide, the CCR7 protein affinity peptide can be chemically modified to extend the half-life, such as cyclization modification, acetylation modification, PAS modification, PEG modification, fatty acid modification, albumin modification, albumin affinity peptide modification, NOTA modification, radionuclide modification, tumor homing peptide coupling, membrane-penetrating peptide coupling, nanocarrier coupling and the like. A series of foreseeable chemical modification methods.

[0037] The fifth aspect of the present invention provides a CCR7 protein detection reagent, comprising the CCR7 protein affinity peptide described in any one of the first aspect.

[0038] The CCR7 protein detection reagent according to the embodiment of the present invention has at least the following beneficial effects: the affinity peptide of the present invention has a good affinity effect on the CCR7 protein and can be used to prepare a CCR7 protein detection reagent.

[0039] In some embodiments of the present invention, the CCR7 protein detection reagent further comprises a developer and / or a tracer.

[0040] The sixth aspect of the present invention provides use of the CCR7 protein affinity peptide as described in any one of the first aspect, or the biomaterial as described in the second aspect, or the pharmaceutical composition as described in the fourth aspect in the preparation of an anti-tumor drug.

[0041] In some embodiments of the present invention, the efficacy of the anti-tumor drug includes: inhibiting the phosphorylation of ERK1 / 2, resisting tumor lymph node metastasis or enhancing the function of immune cells.

[0042] Other features and advantages of the present invention will be set forth in the description which follows. BRIEF DESCRIPTION OF THE DRAWINGS

[0043] The present invention will be further described below with reference to the accompanying drawings and embodiments, wherein: Figure 1 is the molecular structure formula of the parent peptide TC6; Figure 2 This is the mass spectrometry identification result of the parent peptide TC6; Figure 3 The results of the gradient-dependent experiment of the parent peptide TC6 blocking the CCR7-CC19 protein interaction; Figure 4 The results of the gradient-dependent experiment of the parent peptide TC6 blocking the CCR7-CC21 protein interaction; Figure 5 The experimental results of alanine scanning peptides of the parent peptide TC6 blocking the CCR7-CC19 protein interaction; Figure 6The experimental results of the modified peptides TC6-D1~TC6-D10 blocking CCR7-CC19; Figure 7 The results of enzyme degradation experiments of the parent peptide TC6 and the modified peptide TC6-D3 in 10% mouse serum; Figure 8 The effect of the modified peptide TC6-D3 on the phosphorylation level of ERK1 / 2 induced by CCL19; Fig. 9 The effect of the modified peptide TC6-D3 on the phosphorylation level of ERK1 / 2 induced by CCL21; Fig.10 The results of the affinity experiment between the modified peptide TC6-D3 and the CCR7-EGFP fusion protein; Fig.11 The effect of the modified peptide TC6-D3 on the tumor volume of C57BL / 6 mice in the MC38-CCR7 transplanted tumor model; Fig.12 The effect of the modified peptide TC6-D3 on the body weight of C57BL / 6 mice in the MC38-CCR7 transplanted tumor model; Fig.13 The effect of modified peptide TC6-D3 on the popliteal lymph nodes of C57BL / 6 mice in the MC38-CCR7 transplanted tumor model. DETAILED DESCRIPTION

[0044] The following will be combined with the embodiments to clearly and completely describe the concept of the present invention and the technical effects produced, so as to fully understand the purpose, characteristics and effects of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of them. Based on the embodiments of the present invention, other embodiments obtained by those skilled in the art without creative work are all within the scope of protection of the present invention.

[0045] The words "preferably", "more preferably", etc. in the present invention refer to embodiments of the present invention that may provide certain beneficial effects in certain circumstances. However, other embodiments may also be preferred under the same circumstances or other circumstances. In addition, the description of one or more preferred embodiments does not imply that other embodiments are not applicable, nor is it intended to exclude other embodiments from the scope of the present invention.

[0046] In the description of the present invention, the reference term "and / or" includes all and any combinations of one or more of the associated listed items.

[0047] In the description of the present invention, the description with reference to the terms "one embodiment", "some embodiments", "illustrative embodiments", "examples", "specific examples", or "some examples" means that the specific features, structures, materials, or characteristics described in conjunction with the embodiment or example are included in at least one embodiment or example of the present invention. In this specification, the schematic representations of the above terms do not necessarily refer to the same embodiment or example.

[0048] In the description of the present invention, the reference term "amino acid" refers to the basic unit constituting protein, which gives the protein a specific molecular structure and makes its molecule biochemically active. For example, the abbreviations corresponding to the "amino acid" used in the present invention are as follows: alanine (Ala or A), isoleucine (Ile or I), aspartic acid (Asp or D), leucine (Leu or L), phenylalanine (Phe or F), proline (Pro or P), serine (Ser or S), threonine (Thr or T) and valine (Val or V).

[0049] In an embodiment of the present invention, the CHO-K1-mCCR7-EGFP fusion expression cell line and the MC38-mCCR7-GFP cell line are both constructed according to conventional techniques in the art; C57BL / 6 mice (6-8 weeks old, female) were purchased from Zhuhai Baishitong Biotechnology Co., Ltd. and were raised in an SPF animal room after purchase.

[0050] If the specific conditions are not specified in the examples, the experiments were carried out under conventional conditions or conditions recommended by the manufacturer. If the manufacturers of the reagents or instruments are not specified, they are all conventional products that can be purchased commercially.

[0051] Example 1: Acquisition of CCR7 affinity peptide This embodiment provides a CCR7 affinity peptide and a method for screening or designing the CCR7 affinity peptide, which specifically includes the following contents.

[0052] (1) Screening of parent peptide TC6: In this example, phage display technology was used to screen the parent peptide TC6, and the screening steps were as follows: S1. First, B16 cells (melanoma cell line, purchased from Beina Bio) and B16-mCCR7 cells (donated by Professor Yang Xuanming of Shanghai Jiao Tong University) with good growth status were collected, and then washed twice with serum-free medium to prepare a concentration of 1×10 6 cells / mL of cell suspension; S2. Add 400 μL of blocking solution (5 mg / mL BSA) to the B16 cell suspension and place on a rotary shaker at 4°C for 1 h. S3. Resuspend the blocked B16 cells with 200 μL PBS buffer, then add 10 μL phage peptide library (refer to the instructions of Ph.D.™-12 phage display peptide library kit, purchased from New England Biolabs), and incubate at 4°C on a rotary shaker for 2 h; S4. Incubate the supernatant from the previous step with B16-mCCR7 cells on a rotary shaker at 4°C for 2 h. S5, wash 5 times with PBST (pH=5.0) containing 0.1% Tween-20, wash 2 times with PBST (pH= 7.4) containing 0.1% Tween-20, then add 100 μL lysis buffer, pipette several times after addition, and place at room temperature for lysis for 5 minutes; S6. Add 400 μL of elution solution to the above system, elute at room temperature for 30 min, and add 60 μL of neutralization solution; S7. The above system was used for the next round of experiments, and steps (S1) to (S6) were repeated five times for screening.

[0053] S8. After five rounds of screening, phage monoclones that bind to the extracellular segment of the target protein mCCR7 were enriched in each round; S9. Select positive clones for sequencing to obtain a twelve-peptide sequence, namely, a mouse CCR7 affinity peptide sequence, and name it TC6. The amino acid sequence information of TC6 is: LSPLIFVTTPDT (SEQ ID NO. 1).

[0054] The above TC6 is a linear structure, and its amino acids are all in L configuration. The structure and mass spectrometry identification results of TC6 are shown in Figure 1 and Figure 2 shown.

[0055] (2) Acquisition of alanine scanning peptides: In order to analyze the effect of specific amino acids on the activity of the entire polypeptide, the present invention designed the following alanine scanning peptide based on the above TC6 sequence, and its amino acid sequence information is specifically shown in Table 1.

[0056] Table 1: TC6 and alanine scanning peptide sequence information

[0057] Note: The amino acids with capital letters in the table are all "L-configuration" amino acids.

[0058] (3) Obtaining modified peptides: In order to screen out CCR7 affinity peptides with excellent comprehensive performance, the present invention designed the following modified peptides based on the above TC6 sequence, and the amino acid sequence information thereof is specifically shown in Table 2.

[0059] Table 2: TC6 and modified peptide sequence information

[0060] Note: The amino acids indicated by capital letters in the table are all "L-configuration" amino acids, and the amino acids indicated by lowercase letters are "D-configuration" amino acids.

[0061] Example 2: Blocking rate detection This example detects the efficiency of the above-mentioned parent peptide TC6, alanine scanning peptide and modified peptide in blocking the CCR7-CC21 / CC19 protein interaction, and performs statistics. The specific experimental method is as follows: (1) Culture B16-mCCR7 cells in RMPI 1640 medium (containing 10% FBS, 100 U / mL penicillin and 100 μg / mL streptomycin), collect cells in the logarithmic growth phase, add pre-cooled PBS (pH = 7.2) buffer, centrifuge at 4°C, 3000 rpm, wash for 5 min, and place on ice; (2) Take 50 μL of the above peptide solution with gradient concentrations (50 μM, 100 μM, 200 μM, 400 μM, 600 μM, 800 μM) and incubate with B16-CCR7 cells (3×10 5 Cells were incubated for 30 min, and only 50 μL PBS (pH = 7.2) solution was added to both the negative control and the positive control; (3) Add recombinant mCCL19-His or mCCL21-His protein (50 ng) to the incubated system. Add only recombinant mCCL19-His or mCCL21-His protein to the positive control and add PBS (pH = 7.2) solution to the negative control. Mix well and incubate at 4°C for 30 min. (4) Add 5 μL of flow cytometry antibody (anti His APC, purchased from BioLegend) to the solution after incubation in step (3), mix well and incubate at 4°C for 30 min; (5) Add 1 mL of pre-cooled PBS (pH = 7.2) buffer to wash and centrifuge, then resuspend the cells in 200 μL of PBS (pH = 7.2) solution, and then use a flow cytometer (purchased from BD Company, USA) to detect the average fluorescence intensity of the cells, and calculate the blocking rate based on the average fluorescence intensity of each group. The calculation formula for the blocking rate is: Blocking rate = (average fluorescence value of the positive control tube - average fluorescence value of the sample tube) / (average fluorescence value of the positive control tube - average fluorescence value of the negative control tube) × 100%.

[0062] The results of the gradient-dependent experiments of the parent peptide TC6 blocking the CCR7-CC19 protein interaction or the CCR7-CC21 protein interaction were shown in Figure 3 and Figure 4 As shown; the experimental results of alanine scanning peptide blocking CCR7-CC19 protein interaction are shown Figure 5 As shown; the experimental results of the modified peptide blocking the CCR7-CC19 protein interaction are shown Figure 6 shown.

[0063] Furthermore, the blocking rates of the parent peptide TC6, alanine scanning peptide and modified peptide in blocking the CCR7-CC19 protein interaction were statistically analyzed, and the results are shown in Table 3.

[0064] Table 3: Statistical results of the blocking rate of CCR7-CC19 protein interaction

[0065] Note: The amino acids indicated by capital letters in the table are all "L-configuration" amino acids, and the amino acids indicated by lowercase letters are "D-configuration" amino acids.

[0066] The above results show that the parent peptide TC6 has the best blocking effect on the CCR7-CC19 protein interaction and is concentration-dependent. 50 was 175.8±15.6 μM; in addition, the blocking rate of the parent peptide TC6 on the CCR7-CC21 protein interaction also showed concentration dependence, IC 50 It is 255.7±36.7 μM.

[0067] Furthermore, in the above-mentioned alanine scanning peptides, when the first amino acid (leucine) was replaced by alanine, the effect on the CCR7-CC19 protein interaction was the greatest, and its blocking effect decreased most significantly, and even showed a certain promotion effect; while when the 10th amino acid (proline) was replaced by alanine, the effect on the CCR7-CC19 protein interaction was relatively small. Among the above-mentioned modified peptides, TC6-D3 and TC6-D9 both showed good blocking effects on the CCR7-CC19 protein interaction.

[0068] Example 3: Degradation stability test Based on the above blocking rate test results, this example further tested the enzymatic degradation stability of the parent peptide TC6 and the modified peptide TC6-D3. The specific test method is as follows: (1) Weigh the parent peptide TC6 and the modified peptide TC6-D3, dissolve them to 200 μM with physiological saline, add mouse serum to prepare a mixed solution containing 10% (V / V) serum, quickly mix well and place in a metal bath, incubate at 37°C for 48 h, and take out some samples at 0 h, 0.5 h, 1 h, 2 h, 4 h, 8 h, 12 h, 24 h, 36 h and 48 h for subsequent detection; (2) Add 1 / 3 volume of 10% perchloric acid solution to the samples taken at different time points, quickly shake and mix to terminate proteolysis, centrifuge at 4°C and 12,000 g for 15 min, and collect the supernatant; (3) The peptide-serum mixture samples were analyzed by reversed-phase high performance liquid chromatography (RP-HPLC), and the experimental results were statistically analyzed.

[0069] The results of enzymatic degradation of TC6 and TC6-D3 in 10% serum are shown in Figure 7 As shown in the figure, the results of the enzyme degradation stability experiment showed that compared with the parent peptide TC6, the serum stability of the modified peptide TC6-D3 was significantly improved after modification, and it still maintained a high level of concentration at 48 h.

[0070] Example 4: Detection of the inhibitory effect on ERK1 / 2 phosphorylation Based on the above stability test results, this example further tested the inhibitory effect of the modified peptide TC6-D3 on the phosphorylation of ERK1 / 2. The specific detection method is as follows: (1) Collect B16-mCCR7 cells in good condition and culture 1×10 6 Cells were seeded in 6-well plates and cultured overnight before replacing with fresh culture medium. (2) Add the above TC6-D3 peptide to a final concentration of 200 μM, incubate for 30 min, and then add 20 ng / mL CCL19 or CCL21; (3) The whole protein lysate was collected at 0 min, 5 min, 10 min and 20 min, and the expression levels of total ERK1 / 2 protein and phosphorylated ERK1 / 2 (pERK1 / 2) were detected by Western blot.

[0071] Test results such as Figure 8 and Fig. 9 As shown, the modified peptide TC6-D3 can significantly reduce the phosphorylation level of ERK1 / 2 caused by CCL19 / CCL21, indicating that TC6-D3 inhibits the activation of ERK1 / 2 by blocking the CCR7-CCL19 / CCL21 pathway, indicating that it has specificity in blocking CCR7.

[0072] Example 5: Affinity detection Based on the above stability test results, this example further uses microthermophoresis (MST, purchased from Nano Temper Technology Co., Ltd., Germany) to detect the affinity of the modified peptide TC6-D3 of the present invention to mCCR7. The specific detection method is as follows: (1) Preparation of CCR7-EGFP fusion protein: Extract the cell membrane of CHO-K1-mCCR7-EGFP and control cell CHO-K1-EGFP cells. The specific operation steps are based on the instructions of the nuclear-cytoplasmic-membrane preparation kit (purchased from Beijing Prilai Gene Technology Co., Ltd.) and are not repeated here. (2) Determine protein concentration: dilute the extracted membrane protein by half, and obtain 16 protein solutions diluted by half. Detect the fluorescence intensity by MST, and select the concentration with protein fluorescence intensity between 200 and 500. (3) Labeled peptide: Dissolve the modified peptide TC6-D3 to the working concentration, then dilute it by half to obtain 16 times of half-diluted peptide solutions, and then mix the peptide solution with the EGFP fusion protein mixture in a 1:1 ratio; (4) Use a MST-specific capillary to absorb the incubated solution, place it on the instrument tray, and immediately detect the fluorescence intensity. Use the NanoTemper analysis software MO.Affinity Analysis to calculate the affinity (KD value).

[0073] Test results such as Fig.10 As shown, the binding KD value of the modified peptide TC6-D3 to the CCR7-EGFP fusion protein is 403nM, indicating that it has a good affinity effect; while the binding KD value to the EGFP control protein is greater than 1000 μM, indicating that there is no affinity effect.

[0074] Example 6: Anti-tumor effect detection Based on the above test results, this example further tested the anti-tumor effect of the modified peptide TC6-D3 based on the MC38-CCR7-GFP footpad popliteal lymph node metastasis model. The specific method is as follows: (1) Inoculate 20 μL of 1×10 6 MC38-CCR7-GFP cell line (tumor cell) was used to grow the mouse tumor until its volume reached 50 mm. 3 At 4 pm, the mice were randomly divided into two groups and injected with 2 mg / kg or 6 mg / kg of the modified peptide TC6-D3 every day. Normal saline was used as a negative control. The drugs were administered every day for 12 consecutive days. During the administration period, the mice were weighed with an electronic balance and the tumors were measured with a digital vernier caliper every two days. The changes in the tumor volume of the mice were calculated and recorded according to the formula V = 1 / 2 × a (length) × b (width) × c (height); (2) On the 23rd day after tumor inoculation, the popliteal lymph nodes on the tumor-bearing side were removed and the tumor metastasis was observed using a small animal imaging system (purchased from Perkin Elmer, USA).

[0075] The changes of tumor volume and body weight of mice during the administration period with the number of days of inoculation are shown in Fig.11 and Fig.12 As shown in Figure 2, the tumor metastasis of mice was Fig.13 As shown, the modified peptide TC6-D3 has obvious anti-tumor effect and anti-lymph node metastasis inhibition effect, and has no obvious toxic side effects. It can be used to prepare anti-tumor drugs (including anti-tumor immunotherapy drugs or anti-tumor related drugs) or detection reagents and clinical CCR7 molecule tracers targeting CCR7, and has good medical application prospects.

[0076] In summary, the present invention provides a parent peptide or a derived peptide with CCR7 affinity effect and its application. The CCR7 affinity peptide screened by the present invention not only has a good blocking effect on the CCR7-CC21 / CC19 protein interaction, but also can inhibit the phosphorylation of ERK1 / 2 and lymph node metastasis, and can provide a new and effective therapeutic strategy for improving the anti-tumor effect.

[0077] The above is a detailed description of the embodiments of the present invention, but the present invention is not limited to the above embodiments. Various changes can be made within the knowledge of ordinary technicians in the relevant technical field without departing from the purpose of the present invention. In addition, the embodiments of the present invention and the features in the embodiments can be combined with each other without conflict.

Claims

1. A CCR7 protein affinity peptide, characterized in that: The CCR7 protein affinity peptide is shown in any one of A1) to A3): A1), a polypeptide having an amino acid sequence of LSPLIFVTTPDT; A2), a derivative polypeptide obtained by subjecting the 2nd to 12th amino acid residues of the polypeptide as described in A1) to 1 to 3 mutations; A3), a fusion polypeptide obtained by connecting a tag to the N-terminus and / or C-terminus of the polypeptide as described in A1) or A2).

2. The affinity peptide according to claim 1, characterized in that: The amino acid residues in the polypeptide represented by A1) are in L configuration and / or D configuration; Preferably, the polypeptide represented by A1) comprises at least 1, 2, 4, 5, 6, 7, 8, 9, 10, 11 or 12 amino acid residues in D configuration; Preferably, the polypeptide represented by A1) contains at least 2, 4, 5 or 6 D-configuration amino acid residues.

3. The affinity peptide according to claim 1, characterized in that: The polypeptide shown in A1) is a polypeptide having an amino acid sequence as shown in any one of SEQ ID NO.1, SEQ ID NO.14, SEQ ID NO.16 to SEQ ID NO.

23.

4. The affinity peptide according to claim 3, characterized in that: The polypeptide represented by A1) is a polypeptide with an amino acid sequence as represented by SEQ ID NO.1, SEQ ID NO.16, SEQ ID NO.17, SEQ ID NO.21 or SEQ ID NO.22; Preferably, the polypeptide shown in A1) is a polypeptide having an amino acid sequence as shown in SEQ ID NO.1 or SEQ ID NO.

16.

5. The affinity peptide according to any one of claims 1 to 4, characterized in that: The derivative polypeptide is a derivative polypeptide obtained by subjecting the amino acid residues 2 to 12 of the polypeptide as described in A1) to a mutation; Preferably, the derivative polypeptide is a polypeptide having an amino acid sequence as shown in SEQ ID NO.3 to SEQ ID NO.13, and the amino acid residues of the polypeptide are in D configuration.

6. A biomaterial related to the CCR7 protein affinity peptide according to any one of claims 1 to 5, characterized in that: The biological material is any one of C1) to C8): C1), a nucleic acid molecule encoding the CCR7 protein affinity peptide according to any one of claims 1 to 5; C2), an expression cassette containing the nucleic acid molecule described in C1); C3), a recombinant vector containing the nucleic acid molecule described in C1); C4), a recombinant vector containing the expression cassette described in C2); C5), a recombinant biological cell containing the nucleic acid molecule described in C1); C6), a recombinant biological cell containing the expression cassette described in C2); C7), a recombinant biological cell containing the recombinant vector described in C3); C8), a recombinant biological cell containing the recombinant vector described in C4).

7. A method for preparing a CCR7 protein affinity peptide according to any one of claims 1 to 5, characterized in that: The preparation is carried out by using any one of solid phase synthesis method, liquid phase synthesis method or gene recombination expression method.

8. A pharmaceutical composition, characterized in that: It comprises the CCR7 protein affinity peptide according to any one of claims 1 to 5, and a pharmaceutically acceptable carrier.

9. A CCR7 protein detection reagent, characterized in that: Comprising the CCR7 protein affinity peptide according to any one of claims 1 to 5.

10. Use of the CCR7 protein affinity peptide according to any one of claims 1 to 5, the biomaterial according to claim 6, or the pharmaceutical composition according to claim 8 in the preparation of anti-tumor drugs.

Citation Information

Cited By

  • CCR7 affinity peptide, coding nucleic acid and application of CCR7 affinity peptide

    CN121086019A